These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19374161)

  • 1. [AIDS and allergy, two stitches from the same skein: immune system dysfunction].
    Olivares Elegia Mdel P; Naranjo Robalino RM; Lazo González ZM; Cuesta Velazco T
    Rev Alerg Mex; 2009; 56(1):23-6. PubMed ID: 19374161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic vaccines for preventing AIDS: their use with HAART.
    Hoff R; McNamara J
    Lancet; 1999 May; 353(9166):1723-4. PubMed ID: 10347978
    [No Abstract]   [Full Text] [Related]  

  • 3. Prime-boost strategies in DNA vaccines.
    Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
    Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. India targets local HIV strain in test of AIDS vaccine.
    Jayaraman KS
    Nature; 2004 Jan; 427(6971):185. PubMed ID: 14724601
    [No Abstract]   [Full Text] [Related]  

  • 5. Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development.
    Muller S
    Int Rev Immunol; 2004; 23(5-6):423-36. PubMed ID: 15370274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction: Back to basics: mucosal immunity and novel HIV vaccine concepts.
    Broliden K; Haase AT; Ahuja SK; Shearer GM; Andersson J
    J Intern Med; 2009 Jan; 265(1):5-17. PubMed ID: 19093956
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
    Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
    Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune dysregulation in major depression: a critical review of existing evidence.
    Kronfol Z
    Int J Neuropsychopharmacol; 2002 Dec; 5(4):333-43. PubMed ID: 12466033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 25 years of HIV research! ... and what about a vaccine?
    Appay V
    Eur J Immunol; 2009 Aug; 39(8):1999-2003. PubMed ID: 19672891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunologic control of HIV-1 infection. Fantasy or soon reality?].
    Heiken H; Stoll M; Valor L; Weber K; Horvath T; Schmidt RE
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():50-4. PubMed ID: 15011590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T-cell recognition of HIV proteins and peptides.
    Nixon DF; McMichael AJ
    AIDS; 1991 Sep; 5(9):1049-59. PubMed ID: 1718319
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunosuppression and vaccinations].
    Débat Zoguéreh D; Ruiz JM
    Sante; 2000; 10(3):211-9. PubMed ID: 11022154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does VaxGen hide the breakthrough infections?
    Veljkovic V; Müller S; Köhler H
    Lancet; 2003 May; 361(9370):1743-4. PubMed ID: 12767763
    [No Abstract]   [Full Text] [Related]  

  • 16. Candidate AIDS vaccines.
    Graham BS; Wright PF
    N Engl J Med; 1995 Nov; 333(20):1331-9. PubMed ID: 7566026
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.
    Leligdowicz A; Rowland-Jones S
    Expert Rev Vaccines; 2008 Apr; 7(3):319-31. PubMed ID: 18393602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [AIDS vaccine].
    Sikorska EJ
    Pneumonol Alergol Pol; 1991; 59(3-4):146-52. PubMed ID: 1843911
    [No Abstract]   [Full Text] [Related]  

  • 19. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
    Vial PA; Ferreccio C; Abarca K; Ortiz E; Noriega M; Pérez C; Labarca J; Torres M; Ferrés M; González C; Acuña G
    Rev Med Chil; 1996 May; 124(5):525-35. PubMed ID: 9035503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 and its causal relationship to immunosuppression and nervous system disease in AIDS: a review.
    Sotrel A; Dal Canto MC
    Hum Pathol; 2000 Oct; 31(10):1274-98. PubMed ID: 11070121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.